EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC-ND 4.0

Adverse event comparison between glucagon‐like peptide‐1 receptor agonists and other antiobesity medications following bariatric surgery

Jason M Samuels iD, Kevin D Niswender, Christianne L Roumie, Matthew D Spann, C Robb Flynn, Fei Ye, Joseph Blankush, Rebecca Irlmeier, Luke M Funk, Mayur B Patel

Diabetes, Obesity and Metabolism · 2024

DOI: 10.1111/dom.15737 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Diabetes, Obesity and Metabolism, 2024. Verfasst von Jason M Samuels und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Section of Surgical Sciences, Vanderbilt University Medical Center, Nashville, Tennessee, USA. Hauptthemen laut MEDLINE: Anti-Obesity Agents, Bariatric Surgery, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCATS NIH HHS, CSRD VA, National Center for Advancing Translational Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To compare the incidence of adverse events (AEs) related to antiobesity medications (AOMs; glucagon‐like peptide‐1 receptor agonists [GLP‐1RAs] vs. non‐GLP‐1RAs) after bariatric surgery.

Methods

This single‐centre retrospective cohort included patients (aged 16–65 years) who had undergone laparoscopic Roux‐en‐Y gastric bypass or sleeve gastrectomy (cohort entry date) and initiated AOMs. Participants were categorized as users of US Food and Drug Administration (FDA)‐approved, off‐label, or GLP‐1RA AOMs if documented as receiving the medication on or after cohort entry date. Non‐GLP‐1RA AOMs were phentermine, orlistat, topiramate, canagliflozin, dapagliflozin, empagliflozin, naltrexone, bupropion/naltrexone and phentermine/topiramate. GLP‐1RA AOMs included: semaglutide, dulaglutide, exenatide and liraglutide. The primary outcome was AE incidence. Logistic regression was used to determine the association of AOM exposure with AEs.

Results

We identified 599 patients meeting our inclusion criteria, 83% of whom were female. Their median (interquartile range [IQR]) age was 47.8 (40.9–55.4) years. The median duration of surgery to AOM exposure was 30 months. GLP‐1RAs use was not associated with higher odds of AEs: adjusted odds ratio (aOR) 1.1 (95% confidence interval [CI] 0.5–2.6) and aOR 1.1 (95% CI 0.6–2.3) for GLP‐1RA versus FDA‐approved and off‐label AOM use, respectively. AOM initiation ≥12 months after surgery was associated with lower risk of AEs compared to

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Obesity AgentsBariatric SurgeryGlucagon-Like Peptide-1 Receptor AgonistsHumansFemaleMiddle AgedAdultMaleRetrospective StudiesYoung AdultAdolescentAgedLiraglutideExenatideObesity, MorbidGlucagon-Like PeptidesImmunoglobulin Fc FragmentsRecombinant Fusion ProteinsSemaglutide

Stichwörter der Autor:innen

adjuvant weight loss therapybariatric surgeryglucagon‐like peptide‐1 receptor agonistsinadequate weight loss

Substanzen

Anti-Obesity AgentsLiraglutideExenatideGlucagon-Like PeptidesImmunoglobulin Fc FragmentsRecombinant Fusion ProteinsGlucagon-Like Peptide-1 Receptor AgonistsSemaglutidedulaglutide

Autor:innen und Institutionen

  • Department of Surgery, Section of Surgical Sciences, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Tennessee Valley VA Health Care System Geriatric Research Education Clinical Center (GRECC), Nashville, Tennessee, USA.
  • Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Department of Surgery, University of Wisconsin-Madison, Madison, Wisconsin, USA.
  • Department of Surgery, William S. Middleton Veterans Health Administration Hospital, Madison, Wisconsin, USA.

ORCID-Profile: Jason M Samuels

Förderung

  • NCATS NIH HHS
  • CSRD VA
  • National Center for Advancing Translational Sciences

Zitieren

APA

Samuels, J. M., Niswender, K. D., Roumie, C. L., Spann, M. D., Flynn, C. R., Ye, F., Blankush, J., Irlmeier, R., Funk, L. M., & Patel, M. B. (2024). Adverse event comparison between glucagon‐like peptide‐1 receptor agonists and other antiobesity medications following bariatric surgery. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15737

Vancouver

Samuels JM, Niswender KD, Roumie CL, Spann MD, Flynn CR, Ye F, et al. Adverse event comparison between glucagon‐like peptide‐1 receptor agonists and other antiobesity medications following bariatric surgery. Diabetes, Obesity and Metabolism. 2024. doi:10.1111/dom.15737

BibTeX
@article{Samuels2024,
  author = {Samuels, Jason M and Niswender, Kevin D and Roumie, Christianne L and Spann, Matthew D and Flynn, C Robb and Ye, Fei and Blankush, Joseph and Irlmeier, Rebecca and Funk, Luke M and Patel, Mayur B},
  title = {Adverse event comparison between glucagon‐like peptide‐1 receptor agonists and other antiobesity medications following bariatric surgery},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2024},
  doi = {10.1111/dom.15737}
}
Kostenlos starten →